|
U.S. News Gilead and J&J Expand HIV Cocktail PartnershipNovember 16, 2011 Gilead Sciences Inc. and Johnson & Johnson's Tibotec division announced Tuesday they will work together to develop a new HIV pill that contains Tibotec's Prezista and Gilead's Emtriva. The tablet also will include Gilead's drug candidates cobicistat and GS 7340, which are not yet approved. Under the arrangement, Gilead will be responsible for manufacturing the drug, handling the regulatory process and selling the medication. Tibotec will retain co-marketing rights in some countries. The companies also partnered to develop Complera, which combines Gilead's Truvada with J&J's Edurant; it was approved in August. Boston Globe 11.15.2011; Associated Press This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|